Feature | Angiography | April 15, 2016

New Drug Ineffective in Preventing Contrast-Induced Kidney Injury

Placebo-controlled trial found no improvement in rate of acute nephropathy

Toshiba

Kidney ultrasound perfusion exam, courtesy of Toshiba.

April 15, 2016 — Patients treated with CMX-2043 — an investigational drug that has previously shown some ability to protect heart muscle from damage during stenting — saw no improved protection in their kidneys compared to placebo, according to research presented at the American College of Cardiology (ACC) 2016 meeting. 

Contrast media used in angiograms can cause damage to kidney cells, lower urine output and significantly reduce or even stop kidney function, especially in patients with diabetes or chronic kidney disease. According to the National Kidney Foundation, patients with both of these conditions have a 20 to 50 percent risk of kidney injury, also called nephropathy, when given contrast.

Currently, hydrating a patient before the imaging procedure is the best way to prevent contrast-induced kidney injury, but that process takes time and can be impractical in emergency situations.

“Contrast-induced acute kidney injury remains a really significant problem in the population,” said Deepak L. Bhatt, M.D., MPH, FACC, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and lead author of the study. “It remains an unmet clinical need to find drugs or devices or strategies to help reduce the risk.”

The randomized, double-blinded clinical trial recruited 361 patients from 31 medical centers in the United States and Canada. Recruited subjects were previously scheduled for an angiogram with a high likelihood that they would need angioplasty because of a poor stress test or acute coronary syndrome. The subjects also had either a severe loss of kidney function or mild-to- moderate loss of kidney function and another risk factor such as diabetes, low blood pressure or being more than 75 years old. Patients experiencing a heart attack, life-threatening arrhythmia or total kidney failure were excluded.

Patients were split into four groups and intravenously given a small dose, a large dose or two small doses of CMX-2043 — 2.4 mg/kg, 3.6 mg/kg, or two doses of 2.4 mg/kg with 24 hours in between doses, respectively — or a placebo before their angiograms. Researchers followed up with the subjects over a period of 90 days, the primary endpoint being a reduction in kidney injury. The researchers also examined the incidence of major adverse cardiac and kidney events, reduction in heart damage and heart attacks, and major side effects of CMX-2043.

After four days, all four groups had similar rates of kidney injury — 18.6 percent for placebo, 25.6 percent for a small dose, 25.3 percent for a large dose and 18.9 percent for two small doses. Both serum creatinine and glomerular filtration rate tests, common measures of renal health, showed similar kidney function decreases in all four groups after four days.

During the study period, the rates of major heart and kidney events were also similar among the placebo and all three CMX-2043 groups. CMX-2043 did not cause any major side effects in the doses used in this study, Bhatt said. However, he said the prior finding in a smaller study that suggested the drug reduced stenting-related heart attack complications was not confirmed.

“The thought was that this drug had antioxidant and cell membrane stabilizing effects and that these benefits would translate into less kidney cell damage and heart muscle damage,” Bhatt said. “But as is often the case in this field, drugs that seem to be good based on preclinical work, when used in humans don’t always have an effect.”

Bhatt said he is encouraged, though, by the fact that he and his colleagues were able to perform an efficient trial on a group of patients who are notoriously difficult to recruit. Future research can use this model to study other drugs, devices and strategies to prevent contrast-induced kidney injury, he said.

“We showed that such a trial can be done, and in a rigorous way,” Bhatt said. “The challenge now is to find a drug that actually works.”

One possible limitation to the study is the fixed dosing of CMX-2043. While the specific doses and regimens studied by the researchers did not yield any significant kidney protection, larger or more frequent doses may show such benefits.

The trial was funded by Ischemix LLC, the manufacturer of CMX-2043.

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init